AstraZeneca (STU:ZEG) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:ZEG AstraZeneca PLC STU:ZEG
84 GF Score
Price €141.50
GF Value €156.11
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Net Loan?

Net Loan only applies to banks and insurance companies.

STU:ZEG
84GF Score
AstraZeneca PLC STU:ZEG
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AstraZeneca (STU:ZEG) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of €141.50 is trading 9.4% below its estimated GF Value™ of €156.11. GuruFocus considers AstraZeneca to be Fairly Valued.

Key valuation signals for STU:ZEG:

  • Net Loan:
  • GF Value™: €156.11 vs. price of €141.50 (9.4% below fair value)
  • GF Score™: 84/100 with 1 warning sign

No single metric tells the full story. See the STU:ZEG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
84GF Score

Get the complete analysis for STU:ZEG

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€141.50
Price
€156.11
GF Value